Cancer remains the most common cause of death in Taiwan. Digestive tract cancers, including esophageal cancer (9th), gastric cancer (6th), colorectal cancer (3rd), and pancreatic cancer (8th), accounted for nearly one-third of cases of cancer related mortality. Besides, medical costs for digestive tract diseases accounted for 15% of the medical expenditures from National Health Insurance Bureau in Taiwan annually. Therefore, clinical researches aimed to reduce the mortality, morbidity, and medical costs from digestive tract diseases are important. 

Helicobacter pylori (H. pylori) has been shown to be an important causal factor for non-cardiac gastric cancer, MALT type gastric lymphoma, and peptic ulcer disease. Accumulating evidences have suggested that eradication of H. pylori infection could reduce the recurrence rate of peptic ulcer diseases and even reduce the occurrence of gastric cancer. Therefore, research and development of new diagnostic modalities and new therapeutic agents for H. pylori infection and its associated disease is crucial not only in the clinical practice but also in the development of biomedical industry. The prevalence of H. pylori infection remained high and its associated diseases (peptic ulcer disease and gastric cancer) are still common in Taiwan. Researches in Taiwan had performed several important studies on the epidemiology, pathogenesis, diagnosis, and treatment in the field of H. pylori associated diseases. However, in the face of rapidly progress in the biotechnology, it is important to organize a multidisciplinary team.

Colorectal cancer is the most common cancer (incidence) in Taiwan in recent 3 years. Previous studies showed that early diagnosis through screening in asymptomatic subjects can reduce the mortality of colorectal cancer. Modalities for colorectal cancer screening include fecal occult blood test, sigmoidoscopy, colonoscopy, and double contrast barium study. However, the availability, safety, attendance rate, and cost-effectiveness should be taken into consideration in deciding the best screening strategy. Moreover, whether the incidence of colorectal cancer could be reduced through the screening programs also remains unknown. The 1- and 5- year survival rates of pancreatic cancer are 25% and less than 10%, respectively. The poor prognosis was probably attributed to the lack of accurate and convenient early diagnostic tools. Most patients are diagnosed at advanced stage and only 20-30% of them can be treated surgically at the time of diagnosis. However, the 5-year survival rates are also lower than 20% even after surgical resection in patients with localized diseases. Therefore, strategies for early diagnosis and prevention of pancreatic cancer are urgently needed. Taken together, we enrolled basic scientists clinical researchers from different fields (gastroenterologist, surgeon, oncologist, and pathologist) to organize the Digestive Diseases and Helicobacter Clinical Trial Consortium.


Objectives and Missions

  1. To establish the Clinical Trial Consortium for digestive tract diseases and H pylori (HP) associated diseases as a Center of Excellence for gastroenterology researches in Asia-Pacific Regions 
  2. To attract international pharmaceutical companies to perform clinical trials on digestive diseases and HP infection in Taiwan
  3. To help Taiwan pharmaceutical companies develop new therapeutic drugs in the treatment of digestive tract and HP infection
  4. To help Taiwan biotechnology companies develop new diagnostic tools in the detection of digestive diseases and HP infection 
  5. To support investigator initiated studies for new management of digestive diseases and HP infection


Contact Information

Ming-Shiang Wu

  • Professor, Department of Internal Medicine and Primary Care Medicine, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
  • Tel: +886-2-23123456 ext 65043
  • Fax: +886-2-23947899
  • Address: No. 7, Chung-Shan S. Road, Taipei, Taiwan

 Jyh-Ming Liou

  • Attending Physician, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
  • Tel: +886-2-23123456 ext 63541 
  • Fax: +886-2-23947899
  • Address: No. 7, Chung-Shan S. Road, Taipei, Taiwan